HRP20120766T4 - Formulacija za isporuku lijeka u kolonu - Google Patents
Formulacija za isporuku lijeka u kolonu Download PDFInfo
- Publication number
- HRP20120766T4 HRP20120766T4 HRP20120766TT HRP20120766T HRP20120766T4 HR P20120766 T4 HRP20120766 T4 HR P20120766T4 HR P20120766T T HRP20120766T T HR P20120766TT HR P20120766 T HRP20120766 T HR P20120766T HR P20120766 T4 HRP20120766 T4 HR P20120766T4
- Authority
- HR
- Croatia
- Prior art keywords
- formulation according
- drug
- coating
- formulation
- core
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 26
- 238000009472 formulation Methods 0.000 title claims 24
- 230000000112 colonic effect Effects 0.000 title claims 2
- 238000012377 drug delivery Methods 0.000 title 1
- 239000000463 material Substances 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 12
- 239000011248 coating agent Substances 0.000 claims 9
- 238000000576 coating method Methods 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- 238000000034 method Methods 0.000 claims 5
- 229920000642 polymer Polymers 0.000 claims 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 3
- 229920002472 Starch Polymers 0.000 claims 3
- 150000004676 glycans Chemical class 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229920001282 polysaccharide Polymers 0.000 claims 3
- 239000005017 polysaccharide Substances 0.000 claims 3
- 239000008107 starch Substances 0.000 claims 3
- 235000019698 starch Nutrition 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 2
- 229920000945 Amylopectin Polymers 0.000 claims 2
- 229920000856 Amylose Polymers 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229920001525 carrageenan Polymers 0.000 claims 2
- 239000000679 carrageenan Substances 0.000 claims 2
- 229940113118 carrageenan Drugs 0.000 claims 2
- 235000010418 carrageenan Nutrition 0.000 claims 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 150000004702 methyl esters Chemical class 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000008199 coating composition Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000013583 drug formulation Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 239000002861 polymer material Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (24)
1. Formulacija za odgođeno otpuštanje lijeka za isporuku lijeka u kolonu koji sadrži čestice s jezgrom i premaz za jezgru, jezgra sadrži lijek a premaz se sastoji od smjese prvog materijala koji je osjetljiv na napada bakterija kolona i drugog materijala koji ima prag pH od pH 6,5 ili više, naznačena time, da se prvi materijal sastoji od polisaharida odabranog iz skupine koja se sastoji od škroba; amiloze; amilopektina; kitosana; kondroitin sulfata; ciklodekstrina; dekstrana; i carrageenana; pri čemu je otpuštanje lijeka odgođeno do kolona i pri čemu je prag pH drugog materijala kada je pH ispod netopljivog i na ili iznad kojeg je topljiv.
2. Formulacija prema patentnom zahtjevu 1, naznačena time, da je polisaharid škrob koji sadrži najmanje 35% amiloze.
3. Formulacija prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačena time, da je drugi materijal film-oblikovani polimerni materijal.
4. Formulacija prema patentnom zahtjevu 3, naznačena time, da je drugi materijal akrilatni polimer.
5. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da je drugi materijal anionski kopolimer (met)akrilne kiselina i (met)akrilna kiselina C1-4 alkil estera.
6. Formulacija prema patentnom zahtjevu 5, naznačena time, da je drugi materijal anionski kopolimer metakrilne kiseline i metil ester metakrilne kiseline pri čemu je omjer metakrilne kiseline u odnosu na metil ester metakrilne kiseline 1:2.
7. Formulacija prema bilo kojem od patentnih zahtjeva 1-3, naznačena time, da je drugi materijal celulozni polimer.
8. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da je proporcija prvog materijala u odnosu na drugi materijal sve do 50:50.
9. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da je proporcija prvog materijala u odnosu na drugi materijal sve do 35:65.
10. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da je minimalni dijametar čestice najmanje 5 x 10-4m.
11. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da je debljina premaza kako je izmjereno teorijskim izračunom težine ("TWG") premaza formulacije od 5 to 10%.
12. Formulacija prema bilo kojem od patentnih zahtjeva 1-10, naznačena time, da je debljina premaza kako je izmjereno teorijskim izračunom težine ("TWG") premaza formulacije od 15 to 35%.
13. Formulacija prema bilo kojem od patentnih zahtjeva 1-10, naznačena time, da je premaz debljine od 10 µm do 150 µm.
14. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da lijek sadrži najmanje jednu kiselinsku skupinu.
15. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da je lijek protu-upalno sredstvo.
16. Formulacija prema bilo kojem od patentnih zahtjeva 1-13, naznačena time, da je lijek steroid.
17. Formulacija prema bilo kojem od patentnih zahtjeva 1-13, naznačena time, da je lijek antineoplastično sredstvo.
18. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da se koristi u postupku medicinskog liječenja ljudskog ili životinjskog tijela terapijom.
19. Uporaba formulacije u skladu s patentnim zahtjevom 15 patentnog zahtjeva 16, naznačena time, da je za proizvodnju lijeka za liječenje bolesti upale crijeva.
20. Uporaba formulacije prema patentnom zahtjevu 17, naznačena time, da je za proizvodnju lijeka za liječenje karcinoma.
21. Uporaba formulacije prema patentnom zahtjevu 15, naznačena time, da je za proizvodnju lijeka za profilaksu karcinoma.
22. Postupak priprave formulacije za odgođeno otpuštanje lijeka prema patentnom zahtjevu 1, naznačen time, da se rečeni postupak sastoji od:
oblikovanja jezgre koja sadrži lijek; i
premaza jezgre s pripravkom za polimerni premaz koji sadrži smjesu od prvog materijala osjetljivu na napad crijevnih bakterija i drugo materijal kojem prag pH jeste pH 6,5 ili više,
pri čemu prvi materijal sadrži polisaharid odabran iz skupine koja se sastoji od škroba; amilopektina; kitosana; kondroitin sulfata; ciklodekstrina; dekstrana; i carrageenana.
23. Postupak prema patentnom zahtjevu 22, naznačen time, da je jezgra obložena raspršivačem s rečenim pripravkom polimera.
24. Postupak prema patentnom zahtjevu 22 ili patentnom zahtjevu 23, naznačena time, da se sastoji od: oblikovanja vodene disperzije rečenog prvog materijala; oblikovanja alkoholne ili vodene otopine rečenog drugog materijala; i dodavanja najmanje jedne porcije rečene vodene disperzije rečenog prvog materijala u najmanje jednu porciju rečene alkoholne ili vodene otopine rečenog drugog materijala kako bi se oblikovao rečeni pripravak polimernog premaza.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0607534.5A GB0607534D0 (en) | 2006-04-13 | 2006-04-13 | Colonic drug delivery formulation |
EP07732397.0A EP2018159B2 (en) | 2006-04-13 | 2007-04-13 | Colonic drug delivery formulation |
PCT/GB2007/001354 WO2007122374A2 (en) | 2006-04-13 | 2007-04-13 | Colonic drug delivery formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20120766T1 HRP20120766T1 (en) | 2012-10-31 |
HRP20120766T4 true HRP20120766T4 (hr) | 2020-07-10 |
Family
ID=36571851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120766TT HRP20120766T4 (hr) | 2006-04-13 | 2012-09-27 | Formulacija za isporuku lijeka u kolonu |
Country Status (26)
Country | Link |
---|---|
US (6) | US9023368B2 (hr) |
EP (1) | EP2018159B2 (hr) |
JP (5) | JP5176017B2 (hr) |
KR (1) | KR101360122B1 (hr) |
CN (1) | CN101448488B (hr) |
AU (1) | AU2007242648B8 (hr) |
BR (1) | BRPI0710195B8 (hr) |
CA (2) | CA2648658C (hr) |
CY (1) | CY1113307T1 (hr) |
DK (1) | DK2018159T4 (hr) |
ES (1) | ES2390106T5 (hr) |
GB (1) | GB0607534D0 (hr) |
HK (1) | HK1128627A1 (hr) |
HR (1) | HRP20120766T4 (hr) |
IL (2) | IL194632A (hr) |
MX (1) | MX2008013036A (hr) |
NO (1) | NO344029B1 (hr) |
NZ (2) | NZ572760A (hr) |
PL (1) | PL2018159T5 (hr) |
PT (1) | PT2018159E (hr) |
RS (1) | RS52434B2 (hr) |
RU (2) | RU2646825C2 (hr) |
SA (1) | SA07280292B1 (hr) |
SI (1) | SI2018159T2 (hr) |
WO (1) | WO2007122374A2 (hr) |
ZA (1) | ZA200808677B (hr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0607534D0 (en) * | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
ES2425762T3 (es) † | 2008-10-27 | 2013-10-17 | Roquette Freres | Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon |
HUE032368T2 (en) * | 2008-11-13 | 2017-09-28 | Nogra Pharma Ltd | Antisense preparations and methods for their preparation and application |
US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
RS55266B1 (sr) | 2010-11-08 | 2017-02-28 | Albireo Ab | Ibat inhibitori za lečenje bolesti jetre |
WO2013030726A1 (en) | 2011-08-26 | 2013-03-07 | Wockhardt Limited | Programmed drug delivery |
JOP20200144A1 (ar) * | 2012-04-30 | 2017-06-16 | Tillotts Pharma Ag | تركيبة عقار ذو إطلاق متأخر |
SG11201406208QA (en) | 2012-05-03 | 2014-11-27 | Janssen Sciences Ireland Uc | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
MY189394A (en) | 2013-10-29 | 2022-02-09 | Tillotts Pharma Ag | A delayed release drug formulation |
EP2946774B1 (en) * | 2014-05-19 | 2020-04-22 | Tillotts Pharma AG | Modified release coated capsules |
CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
WO2017040864A1 (en) | 2015-09-01 | 2017-03-09 | First Wave Biopharma | Methods and compositions for treating conditions associated with an abnormal inflammatory responses |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) * | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10588864B2 (en) | 2016-03-11 | 2020-03-17 | Gateway Pharmaceuticals LLC | Pharmaceutical compositions for colon-specific delivery |
IL261756B2 (en) | 2016-03-17 | 2023-11-01 | Thiogenesis Therapeutics Inc | Preparations for the controlled release of cysteamine and systemic treatment of disorders sensitive to cysteamine |
EP3257501A1 (en) | 2016-06-14 | 2017-12-20 | Tillotts Pharma AG | Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating |
CN107540761B (zh) * | 2016-06-27 | 2020-08-11 | 中国科学院微生物研究所 | 一种耐酸型普鲁兰多糖衍生物及其制备方法 |
CN106380636B (zh) * | 2016-08-30 | 2019-05-14 | 华南理工大学 | 一种壳聚糖接枝的抗消化淀粉载体材料及其制备方法和应用 |
EP3409688A1 (en) | 2017-05-31 | 2018-12-05 | Tillotts Pharma Ag | Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof |
EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
ES2938609T3 (es) | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión |
WO2019060634A1 (en) | 2017-09-20 | 2019-03-28 | Thiogenesis Therapeutics, Inc. | METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS |
EP3459529A1 (en) | 2017-09-20 | 2019-03-27 | Tillotts Pharma Ag | Preparation of sustained release solid dosage forms comprising antibodies by spray drying |
ES2938608T3 (es) | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2019245449A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
EP3846784A1 (en) | 2018-09-06 | 2021-07-14 | Fachhochschule Nordwestschweiz | Controlled drug release formulation |
EP3662900A1 (en) * | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Colonic drug delivery formulation |
EP3662895A1 (en) | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | A process for manufacturing reducing sugar-free 5-asa tablet cores |
EP3662901A1 (en) * | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing |
EP3662902A1 (en) * | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Colonic drug delivery formulation |
WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
GB201905940D0 (en) | 2019-04-29 | 2019-06-12 | Intract Pharma Ltd | 5-aminolevulinic acid for the local treatment of inflammatory bowel disease |
MX2021013527A (es) | 2019-05-15 | 2021-12-10 | Evonik Operations Gmbh | Proceso para preparar capsulas rellenas, de cubierta dura, con recubrimientos basados en copolimero de (met)acrilato con una maquina para llenar capsulas. |
GB201906906D0 (en) | 2019-05-16 | 2019-07-03 | Intract Pharma Ltd | Novel compositions |
GB201906917D0 (en) | 2019-05-16 | 2019-07-03 | Intract Pharma Ltd | Novel compositions |
KR102104507B1 (ko) * | 2019-08-23 | 2020-04-24 | 브릿지바이오테라퓨틱스(주) | 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법 |
AU2020346061A1 (en) | 2019-09-13 | 2022-03-31 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Autism Spectrum Disorder |
US20240131082A1 (en) | 2019-10-18 | 2024-04-25 | Finch Therapeutics Holdings Llc | Compositions and Methods for Delivering a Bacterial Metabolite to a Subject |
WO2021097288A1 (en) | 2019-11-15 | 2021-05-20 | Finch Therapeutics Holdings Llc | Compositions and methods for treating neurodegenerative diseases |
TW202140049A (zh) | 2020-01-10 | 2021-11-01 | 美商芬奇治療控股有限責任公司 | 用於治療b型肝炎(hbv)及d型肝炎(hdv)之組合物及方法 |
WO2021142238A1 (en) | 2020-01-10 | 2021-07-15 | First Wave Bio, Inc. | Deuterated niclosamide |
WO2021142347A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for non-alcoholic steatohepatitis (nash) |
WO2021142358A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for treating hepatic encephalopathy (he) |
WO2021188564A1 (en) | 2020-03-16 | 2021-09-23 | First Wave Bio, Inc. | Methods of treating covid-19 with a niclosamide compound |
US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
WO2021202806A1 (en) | 2020-03-31 | 2021-10-07 | Finch Therapeutics Holdings Llc | Compositions comprising non-viable fecal microbiota and methods of use thereof |
US11045434B1 (en) | 2020-04-01 | 2021-06-29 | UNION therapeutics A/S | Niclosamide formulations for treating disease |
GB202017863D0 (en) | 2020-11-12 | 2020-12-30 | Intract Pharma Ltd | Novel compositions |
WO2022178294A1 (en) | 2021-02-19 | 2022-08-25 | Finch Therapeutics Holdings Llc | Compositions and methods for providing secondary bile acids to a subject |
WO2023081765A2 (en) * | 2021-11-03 | 2023-05-11 | The University Of Chicago | Prodrug copolymers and polymeric micelles thereof for the delivery of short-chain fatty acids, the promotion of gut health, and the treatment of immune and/or inflammatory conditions and food allergy |
WO2023102491A1 (en) * | 2021-12-01 | 2023-06-08 | Invea Therapeutics, Inc. | Methods for treating gastrointestinal inflammatory disease |
GB202201708D0 (en) | 2022-02-10 | 2022-03-30 | Intract Pharma Ltd | Compositions for oral delivery of biotherapeutics |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA825384B (en) * | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
GB8812490D0 (en) | 1988-05-26 | 1988-06-29 | Agricultural & Food Res | Delayed release formulations |
IT1230576B (it) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
GB8926639D0 (en) | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
ATE185267T1 (de) * | 1990-05-04 | 1999-10-15 | Perio Prod Ltd | System zur arzneistoffabgabe im colon |
US5422121A (en) * | 1990-11-14 | 1995-06-06 | Rohm Gmbh | Oral dosage unit form |
ES2179829T3 (es) * | 1992-09-18 | 2003-02-01 | Yamanouchi Pharma Co Ltd | Preparacion de hidrogel de liberacion prolongada. |
DE69528583T2 (de) * | 1994-04-22 | 2003-07-10 | Yamanouchi Pharma Co Ltd | Kolon-spezifisches arzneistofffreisetzungssystem |
GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
US6248362B1 (en) * | 1997-03-26 | 2001-06-19 | Meiji Seika Kaisha, Ltd. | Large intestinal delivery composite |
CN1475208A (zh) * | 1997-07-01 | 2004-02-18 | �Ʒ� | 舍曲林的缓释剂型 |
GB9722426D0 (en) | 1997-10-23 | 1997-12-24 | Univ London Pharmacy | Controlled release formulations |
GB9724186D0 (en) | 1997-11-14 | 1998-01-14 | British Tech Group | Low temperature coatings |
US6251430B1 (en) * | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
WO1999052512A1 (en) * | 1998-03-27 | 1999-10-21 | Valtion Teknillinen Tutkimuskeskus | Coated starch capsules and a process for producing them |
EP1203590B1 (en) | 1999-08-09 | 2007-07-04 | Dainippon Sumitomo Pharma Co., Ltd. | Solid preparations containing chitosan powder and process for producing the same |
FI20000780A (fi) | 2000-04-03 | 2001-10-04 | Novasso Oy | Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi |
GB2367002A (en) | 2000-09-25 | 2002-03-27 | British Sugar Plc | Coating composition |
GB0203421D0 (en) | 2002-02-13 | 2002-04-03 | Alizyme Therapeutics Ltd | Composition |
CN1201736C (zh) * | 2002-07-19 | 2005-05-18 | 安徽省药物研究所 | 甲硝唑结肠定位缓释制剂 |
US7670627B2 (en) | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
EA200600598A1 (ru) * | 2003-09-19 | 2006-08-25 | Пенвест Фармасьютикалз Ко. | Лекарственные формы замедленного высвобождения |
CZ2004964A3 (cs) * | 2004-09-14 | 2006-03-15 | Pliva-Lachema A. S. | Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo |
CA2578626C (en) * | 2005-06-27 | 2011-07-19 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
JP2009502908A (ja) * | 2005-07-29 | 2009-01-29 | スティッチング グロニンゲン セントル フォー ドラッグ リサーチ | pH制御パルス送達システム、その調製法及び使用法 |
GB0607534D0 (en) * | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
JP6148210B2 (ja) * | 2014-06-17 | 2017-06-14 | 東京エレクトロン株式会社 | 現像方法及びコンピュータ読み取り可能な記録媒体 |
-
2006
- 2006-04-13 GB GBGB0607534.5A patent/GB0607534D0/en not_active Ceased
-
2007
- 2007-04-13 AU AU2007242648A patent/AU2007242648B8/en active Active
- 2007-04-13 NZ NZ572760A patent/NZ572760A/xx unknown
- 2007-04-13 PL PL07732397T patent/PL2018159T5/pl unknown
- 2007-04-13 WO PCT/GB2007/001354 patent/WO2007122374A2/en active Application Filing
- 2007-04-13 DK DK07732397.0T patent/DK2018159T4/da active
- 2007-04-13 US US11/735,248 patent/US9023368B2/en active Active
- 2007-04-13 CA CA2648658A patent/CA2648658C/en active Active
- 2007-04-13 KR KR1020087027321A patent/KR101360122B1/ko active IP Right Grant
- 2007-04-13 RU RU2012153207A patent/RU2646825C2/ru active
- 2007-04-13 ES ES07732397T patent/ES2390106T5/es active Active
- 2007-04-13 RU RU2008144700/15A patent/RU2478372C2/ru active
- 2007-04-13 NZ NZ778023A patent/NZ778023A/en unknown
- 2007-04-13 EP EP07732397.0A patent/EP2018159B2/en active Active
- 2007-04-13 RS RS20120404A patent/RS52434B2/sr unknown
- 2007-04-13 BR BRPI0710195A patent/BRPI0710195B8/pt active IP Right Grant
- 2007-04-13 JP JP2009504820A patent/JP5176017B2/ja active Active
- 2007-04-13 CN CN200780018366XA patent/CN101448488B/zh active Active
- 2007-04-13 CA CA2825758A patent/CA2825758A1/en not_active Abandoned
- 2007-04-13 PT PT07732397T patent/PT2018159E/pt unknown
- 2007-04-13 MX MX2008013036A patent/MX2008013036A/es active IP Right Grant
- 2007-04-13 SI SI200731022T patent/SI2018159T2/sl unknown
- 2007-06-06 SA SA7280292A patent/SA07280292B1/ar unknown
-
2008
- 2008-10-07 IL IL194632A patent/IL194632A/en active IP Right Grant
- 2008-10-10 ZA ZA2008/08677A patent/ZA200808677B/en unknown
- 2008-10-14 NO NO20084292A patent/NO344029B1/no unknown
-
2009
- 2009-07-27 HK HK09106896.3A patent/HK1128627A1/xx unknown
-
2012
- 2012-09-24 CY CY20121100871T patent/CY1113307T1/el unknown
- 2012-09-27 HR HRP20120766TT patent/HRP20120766T4/hr unknown
- 2012-10-19 JP JP2012231560A patent/JP2013047250A/ja not_active Withdrawn
-
2015
- 2015-03-18 JP JP2015054167A patent/JP2015134806A/ja not_active Withdrawn
- 2015-04-01 US US14/676,225 patent/US9993435B2/en active Active
-
2017
- 2017-01-24 JP JP2017009975A patent/JP6273387B2/ja active Active
- 2017-02-19 IL IL250674A patent/IL250674B/en active IP Right Grant
- 2017-12-07 US US15/834,436 patent/US10369112B2/en active Active
-
2018
- 2018-01-05 JP JP2018000411A patent/JP2018076362A/ja active Pending
-
2019
- 2019-03-15 US US16/354,683 patent/US10668023B2/en active Active
-
2020
- 2020-02-24 US US16/798,676 patent/US10758491B2/en active Active
- 2020-04-17 US US15/929,260 patent/US10857103B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120766T4 (hr) | Formulacija za isporuku lijeka u kolonu | |
Lee et al. | Preparation and release characteristics of polymer-coated and blended alginate microspheres | |
DK2659881T3 (en) | Delayed release drug formulation | |
Günter et al. | Preparation and release characteristics of mesalazine loaded calcium pectin-silica gel beads based on callus cultures pectins for colon-targeted drug delivery | |
HRP20150734T1 (hr) | Polimerni materijal | |
BR112012008626A2 (pt) | forma farmacêutica oral sólida com liberação modificada de pelo menos um ingrediente ativo | |
JPH0881392A (ja) | 薬剤形状物用被覆剤及び結合剤及び薬剤形状物 | |
Liu et al. | Synthesis of chitosan-based nanohydrogels for loading and release of 5-fluorouracil | |
BR112013028453B1 (pt) | Uso de uma composição de revestimento, formas de dosagem farmacêuticas ou nutracêuticas gastrorresistentes, e composição do polímero do núcleo/invólucro | |
HRP20200780T1 (hr) | Formulacija za kontrolirano otpuštanje hidrokortizona | |
Kurakula et al. | Formulations for polymer coatings | |
JP2019509345A5 (hr) | ||
Chauhan et al. | Formulation and evaluation of Prednisolone tablet for colon targeted drug delivery system | |
Tran et al. | Current film coating designs for colon-targeted oral delivery | |
Patel et al. | Design, development and in vitro evaluation of Mesalamine tablets containing Pectin and Chitosan for colon-specific drug delivery | |
IL235283A (en) | Formula for drug with delayed release | |
HRP20240303T1 (hr) | Osmotski oblici doziranja koji sadrže deutetrabenazin i postupci njihove upotrebe | |
CA3111353A1 (en) | Controlled drug release formulation | |
M Obeidat et al. | Novel salted anionic-cationic polymethacrylate polymer blends for sustained release of acidic and basic drugs | |
CN102579400B (zh) | 一种可控制定时释放磁性药物微胶囊的制备方法 | |
CN107296795A (zh) | 一种抗肿瘤药物缓释微球制剂 | |
Contri et al. | In vitro release and ex vivo skin permeation of a nanostructured formulation for topical delivery of capsaicinoids | |
NZ748404A (en) | Colonic drug delivery formulation | |
NZ748404B2 (en) | Colonic drug delivery formulation | |
NZ785519B2 (en) | Colonic drug delivery formulation |